Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 15/20 | 0.81 |
| ▸ | ADRB3 | P13945 | 8/20 | 0.74 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695262 | 1.00 | ADRB2 (0.81) | ADRB2ADRB3ADRB1KDM4EGAA | |
| SCHEMBL6695265 | 1.00 | ADRB2 (0.81) | ADRB2ADRB3ADRB1KDM4EGAA | |
| SCHEMBL6691687 | 0.87 | ADRB2 (0.70) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL6141170 | 0.87 | ADRB2 (0.70) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL6691677 | 0.87 | ADRB2 (0.70) | ADRB2ADRB3ADRB1DRD2PGR | |
| Milveterol SCHEMBL185356 | 0.85 | ADRB2 (1.00) | ADRB2ADRB3ADRB1 | |
| Milveterol SCHEMBL29448200 | 0.85 | ADRB2 (1.00) | ADRB2ADRB3ADRB1 | |
| Milveterol SCHEMBL168972 | 0.85 | ADRB2 (1.00) | ADRB2ADRB3ADRB1 | |
| Milveterol SCHEMBL4385046 | 0.85 | ADRB2 (1.00) | ADRB2ADRB3ADRB1 | |
| Milveterol SCHEMBL265694 | 0.85 | ADRB2 (1.00) | ADRB2ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1507754-A1 | ALKOXY ARYL BETA-2 ADRENERGIC RECEPTOR AGONISTS | Theravance, Inc. (US) | 2005-02-23 | — | — | EP | claimed |
| US-6747043-B2 | TREATING PULMONARY DISEASE, PRE-TERM LABOR, NEUROLOGICAL DISORDERS, CARDIAC DISORDERS, AND INFLAMMATION | THERAVANCE, INC. | 2004-06-08 | — | — | US | claimed |
| US-20040006102-A1 | Alkoxy aryl beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-01-08 | — | — | US | claimed |
| WO-2003099764-A1 | ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2003-12-04 | — | — | WO | claimed |
| US-6747043-B2 | TREATING PULMONARY DISEASE, PRE-TERM LABOR, NEUROLOGICAL DISORDERS, CARDIAC DISORDERS, AND INFLAMMATION | THERAVANCE, INC. | 2004-06-08 | — | — | US | disclosed |
| US-20040006102-A1 | Alkoxy aryl beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006102-A1 | Alkoxy aryl beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB3 5/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.